Disappointing phase III data for Avicena drug candidate
Study data showed no statistically significant difference between ALS-02 5g per day and placebo with regard to the study’s primary and secondary endpoints, which consisted of various measures
Study data showed no statistically significant difference between ALS-02 5g per day and placebo with regard to the study’s primary and secondary endpoints, which consisted of various measures
Li-Fraumeni syndrome (LFS) is a rare inherited genetic disorder that greatly increases the risk of developing several types of cancer typically with initial occurrence at a young age.
Maxygen achieved this latest milestone by developing a manufacturing process for the product candidates. Factor VII is a natural protein with a pivotal role in blood coagulation and
Gamma secretase plays a role in the production of beta-amyloid, a major component of plaque in the brain, which is thought to be a cause of Alzheimer’s disease.
Under terms of the agreement, Labopharm will supply Grunenthal with finished packaged product and will receive revenue from sales at rates in proportion with those of previous licensing
The study, published in the peer-reviewed medical journal CHEST, suggests that the disease in its earliest form may be more difficult to spot in women because it may
The new drug application will be primarily based on data from the company’s SMART trial, which was conducted at 94 centers in North America, Europe and Australia and
The company obtained an exclusive, worldwide license from Harvard Medical School’s Beth Israel Deaconess Medical Center in February 2005 for the development of a “super” EPO, a more
Starting May 15th, patients in the trial will be given doses in an escalating fashion to provide pharmacokinetics data. This study is being conducted at The Diabetes &
Tamiflu (oseltamivir phosphate), the leading prescription antiviral medication for prevention and treatment of influenza, is the only oral antiviral that has shown activity in vitro and in animal